SOURCE: Nexvet Biopharma

Nexvet Biopharma

February 18, 2014 06:00 ET

Nexvet Biopharma to Present at the Cowen and Company 34th Annual Health Care Conference on March 5, 2014

MELBOURNE, AUSTRALIA--(Marketwired - Feb 18, 2014) - Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that Dr Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the 34th Annual Cowen Health Care Conference in Boston on Wednesday, March 5, 2014 at 11:30 AM EST.

Dr Heffernan will provide an overview of Nexvet's pioneering developments in the field of 100% species-specific monoclonal antibody therapies for chronic conditions in pets (companion animals).

About Nexvet (www.nexvet.com)
Nexvet Biopharma is pioneering the field of monoclonal antibody therapies for companion animals (e.g. dogs and cats) using its proprietary PETisation™ platform technology, which uniquely produces therapies 100% customised to target species. The Nexvet portfolio focuses on areas of greatest unmet medical need such as chronic pain and inflammatory diseases, in addition to a significant pipeline of medically important products.

The area of biologics has become a massive growth area in human medicine, responsible for many of the most successful drugs on the market due to their clinical effectiveness, specificity and excellent side-effect profiles. Nexvet's team have international track records in the development of both human biologics and veterinary drugs, and are committed to developing biologics to drive innovation in the $20 billion global veterinary pharmaceuticals market. Nexvet is a privately held company based in Melbourne (Australia) with global operations, partners and investors. 

Contact Information